persons palm in close up photography
  • Sustained Improvements Post-Treatment: Adults who previously responded to amlitelimab and continued treatment showcased notable and maintained improvements in atopic dermatitis symptoms for 28 weeks.
  • Consistent Safety Profile: The safety profile at week 52 aligns with the week 24 data, with amlitelimab being well-tolerated and no new safety concerns identified.
  • Potential for Quarterly Dosing: The enduring response supports the investigation of a quarterly dosing regimen, currently being explored in the Phase III OCEANA program. This regimen involves a 250 mg dose every 12 weeks following an initial 500 mg loading dose.
  • Impact on Biomarkers: The significant reduction in biomarkers suggests that OX40L inhibition – a mechanism not depleting T lymphocytes – modulates the immune response for long-term disease control.
  • Broader Implications: Amlitelimab is one of the 12 potential blockbusters in Sanofi’s leading immunology pipeline, with Phase II results in asthma treatment expected in the second half of 2024 and three additional Phase II studies launching by year-end.

Paris, France — Sanofi Monday shared the latest findings from Part 2 of the Phase IIb STREAM-AD study on the experimental drug amlitelimab.

They revealed sustained improvements in the signs and symptoms of moderate to severe atopic dermatitis over 28 weeks.

These results were presented at the 2024 American Academy of Dermatology (AAD) Congress in San Diego, highlighting amlitelimab’s potential as a leading treatment option.

Atopic dermatitis, often referred to as eczema, is a chronic skin condition characterized by dry, itchy, and inflamed skin. It’s most commonly seen in children but can also affect adults. The exact cause of atopic dermatitis is unknown, but it’s believed to be linked to an overactive immune response to environmental triggers and a dysfunction in the skin barrier

The findings reinforce the potential of amlitelimab to provide a sustained therapeutic response, bolstering its status as a top candidate in the category for the treatment of atopic dermatitis. With its promising efficacy and safety profile, amlitelimab is poised to make a significant impact in dermatology and immunology.

By Lisa Luckas

Lisa Luckas is a Sr. Business News Editor at Nobot.News.

Leave a Reply

Your email address will not be published. Required fields are marked *

GDPR Cookie Consent with Real Cookie Banner